Cargando…

Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR

BACKGROUND: Standard platinum-based therapy for ovarian cancer is inefficient against ovarian clear cell carcinoma (OCCC). OCCC is a distinct subtype of epithelial ovarian cancer. OCCC constitutes 25% of ovarian cancers in East Asia (Japan, Korea, China, Singapore) and 6–10% in Europe and North Amer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chien, Wenwen, Tyner, Jeffrey W., Gery, Sigal, Zheng, Yueyuan, Li, Li-Yan, Gopinatha Pillai, Mohan Shankar, Nam, Chehyun, Bhowmick, Neil A., Lin, De-Chen, Koeffler, H. Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122390/ https://www.ncbi.nlm.nih.gov/pubmed/37087441 http://dx.doi.org/10.1186/s13048-023-01160-y

Ejemplares similares

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
por: Kinose, Yasuto, et al.
Publicado: (2023)

Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
por: Nam, Ah-Rong, et al.
Publicado: (2020)

ARID1A Deficiency Regulates Anti-Tumor Immune Response in Esophageal Adenocarcinoma
por: Zhang, Le, et al.
Publicado: (2023)

Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells
por: Rødland, Gro Elise, et al.
Publicado: (2021)

Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress
por: Saini, Priyanka, et al.
Publicado: (2015)

Clinical Candidates Targeting the ATR–CHK1–WEE1 Axis in Cancer
por: Gorecki, Lukas, et al.
Publicado: (2021)

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
por: Chan, Daniel, et al.
Publicado: (2013)

The ATR-WEE1 kinase module inhibits the MAC complex to regulate replication stress response
por: Wang, Lili, et al.
Publicado: (2021)

CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
por: Xu, Haineng, et al.
Publicado: (2021)

MNK1 and MNK2 enforce expression of E2F1, FOXM1, and WEE1 to drive soft tissue sarcoma
por: Ke, Xin-Yu, et al.
Publicado: (2021)

EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma
por: Shi, Xianping, et al.
Publicado: (2020)

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma
por: Xing, Lijie, et al.
Publicado: (2020)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
por: Serra, Violeta, et al.
Publicado: (2022)

Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
por: Jin, Juan, et al.
Publicado: (2018)

Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
por: Mak, Joyce P.Y., et al.
Publicado: (2014)

LNK (SH2B3): paradoxical effects in ovarian cancer
por: Ding, Ling-Wen, et al.
Publicado: (2014)

Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication
por: Sørensen, Claus Storgaard, et al.
Publicado: (2012)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
por: Li, Siyu, et al.
Publicado: (2022)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer
por: Feng, Wenlong, et al.
Publicado: (2020)

Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma
por: Gopinatha Pillai, Mohan Shankar, et al.
Publicado: (2023)

Air raids and the 'Wee' Hospital.
por: Logan, C. J. H.
Publicado: (2003)

ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
por: Seidel, Philipp, et al.
Publicado: (2022)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2018)

WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability
por: Zhang, Minghui, et al.
Publicado: (2017)

Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2016)

Correction: Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia
por: Sun, Haibo, et al.
Publicado: (2017)

HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer
por: Dou, Zhiyuan, et al.
Publicado: (2022)

A Wee Lesson in Science Communication
por: King, Emma
Publicado: (2004)

Pedicures, wees alert op ‘coronatenen’
por: van Putten, Margreet
Publicado: (2020)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

Mutation analysis of the ATR gene in breast and ovarian cancer families
por: Heikkinen, Katri, et al.
Publicado: (2005)

ODF2L acts as a synthetic lethal partner with WEE1 inhibition in epithelial ovarian cancer models
por: Li, Jie, et al.
Publicado: (2023)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011)

Deficiency of CCAAT/Enhancer Binding Protein-Epsilon Reduces Atherosclerotic Lesions in LDLR−/− Mice
por: Okamoto, Ryoko, et al.
Publicado: (2014)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib
por: Chien, Wenwen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_netlhe55nqdjeue2ok6brckhid